From Barron’s

Novo Nordisk _ CEO Lars Fruergaard Jørgensen will step down as CEO of the Danish maker of GLP-1 drugs Ozempic and Wegovy.

It was a “mutual agreement,” Novo said in a statement Friday. The search for Fruergaard Jørgensen’s successor is ongoing, the company added.

Novo Nordisk stock was up about 1.8% in Denmark. Its American depositary receipts _ were down 2.8% to $64.20.

submitted by /u/himynameis_
[link] [comments]

Leave a Reply

Your email address will not be published. Required fields are marked *